Cellular senescence, a defense mechanism characterized by stable cell cycle arrest with maintained metabolic activity, plays a dual role in tumor biology, influencing cancer initiation, progression and treatment response.[19, 20] While CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) have been FDA‐approved for HR+/HER2‐ breast cancer treatment,[21, 22] their potential in triple‐negative breast cancer warrants further investigation. Here, CDK4 is linked to neoplasm.